Ken Griffin Novo Nordisk A S Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Novo Nordisk A S stock. As of the latest transaction made, Citadel Advisors LLC holds 1,407,200 shares of NVO stock, worth $158 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

1,407,200

Previous 1,356,200 3.76%

Holding current value

$158 Million

Previous $174 Million 15.35%

% of portfolio

0.04%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$122.71 - $146.91 $11.7 Million - $14.1 Million	-95,718 Reduced 9.88%	873,106 $125 Million
Q1 2024 May 15, 2024	BUY	$102.11 - $135.92 $44.3 Million - $58.9 Million	433,417 Added 80.95%	968,824 $124 Million
Q4 2023 Feb 14, 2024	BUY	$87.78 - $105.45 $18.2 Million - $21.8 Million	207,041 Added 63.05%	535,407 $55.4 Million
Q3 2023 Nov 14, 2023	BUY	$90.94 - $199.54 $10 Million - $22 Million	110,246 Added 50.54%	328,366 $29.9 Million
Q2 2023 Aug 14, 2023	SELL	$155.98 - $172.65 $1.85 Million - $2.05 Million	-11,875 Reduced 5.16%	218,120 $35.3 Million
Q1 2023 May 15, 2023	SELL	$132.34 - $159.14 $23.3 Million - $28 Million	-175,803 Reduced 43.32%	229,995 $36.6 Million
Q4 2022 Feb 14, 2023	BUY	$102.55 - $135.33 $10.5 Million - $13.8 Million	102,333 Added 33.72%	405,798 $54.9 Million
Q3 2022 Nov 14, 2022	SELL	$95.28 - $116.93 $13.4 Million - $16.5 Million	-140,737 Reduced 31.68%	303,465 $30.2 Million
Q2 2022 Aug 15, 2022	BUY	$103.24 - $121.81 $40 Million - $47.2 Million	387,523 Added 683.72%	444,202 $49.5 Million
Q1 2022 May 16, 2022	BUY	$93.1 - $112.54 $996,635 - $1.2 Million	10,705 Added 23.28%	56,679 $6.29 Million
Q4 2021 Feb 14, 2022	SELL	$95.88 - $117.08 $29.9 Million - $36.6 Million	-312,213 Reduced 87.16%	45,974 $5.15 Million
Q3 2021 Nov 15, 2021	BUY	$84.42 - $106.62 $11.5 Million - $14.5 Million	135,708 Added 61.0%	358,187 $34.4 Million
Q2 2021 Aug 16, 2021	SELL	$67.66 - $84.76 $303,455 - $380,148	-4,485 Reduced 1.98%	222,479 $18.6 Million
Q1 2021 May 17, 2021	SELL	$67.06 - $75.82 $16.1 Million - $18.2 Million	-240,289 Reduced 51.43%	226,964 $15.3 Million
Q4 2020 Feb 16, 2021	BUY	$63.89 - $73.8 $6.99 Million - $8.07 Million	109,371 Added 30.56%	467,253 $32.6 Million
Q3 2020 Nov 16, 2020	BUY	$63.69 - $70.22 $13 Million - $14.3 Million	203,523 Added 131.85%	357,882 $24.8 Million
Q2 2020 Aug 14, 2020	BUY	$58.54 - $67.94 $8.12 Million - $9.43 Million	138,788 Added 891.32%	154,359 $10.1 Million
Q1 2020 May 15, 2020	SELL	$49.46 - $64.78 $11.4 Million - $14.9 Million	-230,167 Reduced 93.66%	15,571 $937,000
Q4 2019 Feb 14, 2020	SELL	$49.86 - $58.26 $1.55 Million - $1.81 Million	-31,017 Reduced 11.21%	245,738 $14.2 Million
Q3 2019 Nov 14, 2019	SELL	$47.54 - $53.43 $26.6 Million - $29.9 Million	-559,491 Reduced 66.91%	276,755 $14.3 Million
Q2 2019 Aug 14, 2019	BUY	$46.79 - $52.47 $15.6 Million - $17.4 Million	332,358 Added 65.96%	836,246 $42.7 Million
Q1 2019 May 15, 2019	BUY	$46.36 - $52.63 $22.5 Million - $25.5 Million	484,499 Added 2498.83%	503,888 $0
Q4 2018 Feb 14, 2019	SELL	$41.54 - $47.25 $6.46 Million - $7.35 Million	-155,461 Reduced 88.91%	19,389 $893,000
Q3 2018 Nov 13, 2018	BUY	$46.76 - $51.24 $5.69 Million - $6.24 Million	121,766 Added 229.38%	174,850 $0
Q2 2018 Aug 10, 2018	SELL	$44.29 - $50.42 $7.79 Million - $8.87 Million	-175,985 Reduced 76.83%	53,084 $0
Q1 2018 May 11, 2018	BUY	$48.49 - $58.14 $6.18 Million - $7.41 Million	127,410 Added 125.33%	229,069 $11.3 Million
Q4 2017 Feb 09, 2018	SELL	$47.53 - $53.73 $7.47 Million - $8.45 Million	-157,193 Reduced 60.73%	101,659 $5.46 Million
Q3 2017 Nov 09, 2017	BUY	$41.15 - $49.22 $10.7 Million - $12.7 Million	258,852	258,852 $12.5 Million

Others Institutions Holding NVO

# of Institutions

1,971

Shares Held

320M

Call Options Held

5.16M

Put Options Held

4.96M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $253B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account